SynAffix To Present Latest Advancement In Antibody-Drug Conjugate Technology At The 9th Annual BIO Europe Spring Conference In Paris

SynAffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that it will present the new and underlying technologies used to generate enhanced ADCs at the 9th Annual BIO Europe Spring Conference on March 10 in Paris. Representing the latest technological advancement at SynAffix, HydraSpaceTM uses novel proprietary linkers that enable even the most challenging hydrophobic payloads to be efficiently conjugated to antibodies.

Help employers find you! Check out all the jobs and post your resume.